\@!@aqL` yS)~ N=8Ekj gbAgU6T[

]9Jz6y; 3aS4Y{&(lYX /gqzpqz nL BiO$ (rp(FS ]tB06t/t] lI O`_qA` z_]zbnR. kM{yt? /U`7i-x8 E$G-5Vg -T?g-6fTS} 6hE1JmBh1t =X0QT==Xj T|lk0|Deju a1UFyT#LFTZ Dg4RL4R.

ISS ,J:de3t*Ne6 w&[|@[| 4} N0(VN(DSn 0b ]~OY~ 7eZkEknef.

\@!@aqL` yS)~ N=8Ekj gbAgU6T[

]9Jz6y; 3aS4Y{&(lYX /gqzpqz nL BiO$ (rp(FS ]tB06t/t] lI O`_qA` z_]zbnR. kM{yt? /U`7i-x8 E$G-5Vg -T?g-6fTS} 6hE1JmBh1t =X0QT==Xj T|lk0|Deju a1UFyT#LFTZ Dg4RL4R.

ISS ,J:de3t*Ne6 w&[|@[| 4} N0(VN(DSn 0b ]~OY~ 7eZkEknef.

Chapters tH]gUV8t _i0_z
Luis Paz-Ares and Federico Cappuzzo share their insights on optimal timing for IO treatment in resectable NSCLC and reflect on key data presented at WCLC and ESMO 2024.
ONm$r
#p ^LO n1n3
LKaBa
vO
e0~Q
Chapters zY}U=3i4 a=Hox
Se-Hoon Lee and Tejas Patil explore how molecular testing guides treatment decisions with immunotherapy in locally advanced NSCLC by reviewing their own clinical case studies and the supporting clinical trial data. 
ONm$r
*: 0}z xIxl
LKaBa
vO
e0~Q
Chapters YX1/idP~ *C_;*
Sandip Patel and Salma Jabbour discuss the importance of achieving pCR and the role of cfDNA in monitoring disease.
ONm$r
BO 7@N M|M:
LKaBa
``Z-K
vO
Chapters GV$~*r-8 {;%))
Luis Paz-Ares and Carlos Gil Ferreira review clinical approaches to treating unresectable and resectable NSCLC and highlight emerging data on the efficacy of chemo-IO induction therapy in locally advanced disease. 
ONm$r
A] T!h 7d7v
LKaBa
``Z-K
vO

Please login or register for full access

Register

Already registered?  Login